OptimizeRx (OPRX) Expected to Announce Quarterly Earnings on Wednesday

OptimizeRx (NASDAQ:OPRX) is anticipated to announce its earnings results after the market closes on Wednesday, March 26th. Analysts expect the company to announce earnings of $0.27 per share and revenue of $30.36 million for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

OptimizeRx Stock Up 4.3 %

OPRX stock opened at $9.00 on Tuesday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The company’s 50-day moving average price is $5.92 and its 200 day moving average price is $5.93. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $14.13. The company has a market cap of $165.79 million, a P/E ratio of -6.77 and a beta of 1.31.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on OPRX shares. B. Riley raised OptimizeRx to a “strong-buy” rating in a research note on Wednesday, March 12th. JMP Securities reiterated a “market outperform” rating and set a $8.00 target price on shares of OptimizeRx in a research report on Thursday, February 6th. Royal Bank of Canada restated a “sector perform” rating and issued a $6.00 price target (down previously from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. Lake Street Capital reiterated a “buy” rating and issued a $11.00 price objective on shares of OptimizeRx in a research report on Tuesday, December 24th. Finally, Stephens assumed coverage on shares of OptimizeRx in a research note on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.06.

Insider Activity at OptimizeRx

In other news, Director James Paul Lang purchased 321,408 shares of the stock in a transaction dated Friday, March 14th. The stock was acquired at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the acquisition, the director now directly owns 389,452 shares in the company, valued at $2,959,835.20. This represents a 472.35 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.10% of the stock is currently owned by corporate insiders.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.